Literature DB >> 12220382

Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis.

M K Sharief1, M A Noori, M R Douglas, Y K Semra.   

Abstract

Programmed cell death (apoptosis) is critical for the normal development and homeostasis of the immune system. There is emerging evidence that failure of apoptosis to eliminate potentially pathogenic, autoreactive T lymphocytes may be involved in the pathogenesis of multiple sclerosis (MS). This failure is related to multiple abnormalities of apoptosis-regulatory molecules that involve survivin, a recently described cell cycle-regulated anti-apoptosis protein. In this study, we investigated the relationship between survivin expression in peripheral T lymphocytes and clinical features of MS. We detected a significant over-expression of survivin in mitogen stimulated T lymphocytes from patients with active MS when compared with corresponding expression in patients with stable MS or those with inflammatory and non-inflammatory neurologic disorders. This over-expression of survivin in patients with active MS correlated with cellular resistance to apoptosis and with features of disease activity, such as disease duration and the number of enhanced lesions on cranial magnetic resonance imaging. There was no correlation between cellular survivin levels and the expression of other apoptosis-inhibitory proteins, such as Bcl-2 and Fas-associated death domain-like interleukin-1beta-converting enzyme inhibitory protein (FLIP). Our findings indicate that cellular over-expression of the novel anti-apoptosis protein survivin is a feature of clinically active MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220382     DOI: 10.1046/j.1468-1331.2002.00454.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  10 in total

1.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

Review 2.  Role of the Survivin gene in pathophysiology.

Authors:  Fengzhi Li; Michael G Brattain
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 3.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease.

Authors:  Heitor S P de Souza; Gail A West; Nancy Rebert; Carol de la Motte; Judy Drazba; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2012-06-26       Impact factor: 22.682

5.  The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model.

Authors:  Xiangyang Zhang; Michael Ciesielski; Robert A Fenstermaker; Henry J Kaminski; Linda L Kusner
Journal:  J Immunol       Date:  2020-08-24       Impact factor: 5.422

6.  Polymorphisms of BIRC5 Gene is Associated with Chronic HBV Infection in Iranian Population.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb
Journal:  Indian J Clin Biochem       Date:  2019-01-02

7.  Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients.

Authors:  Dariush Rahban; Forogh Mohammadi; Mehdi Alidadi; Taha Ghantabpour; Pedram Abbasi Ghasem Kheyli; Majid Ahmadi
Journal:  BMC Immunol       Date:  2019-08-22       Impact factor: 3.615

Review 8.  Environmental Influencers, MicroRNA, and Multiple Sclerosis.

Authors:  Eiman Ma Mohammed
Journal:  J Cent Nerv Syst Dis       Date:  2020-01-20

Review 9.  Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies.

Authors:  Navid Shomali; Marwah Suliman Maashi; Behzad Baradaran; Amin Daei Sorkhabi; Aila Sarkesh; Hamed Mohammadi; Maryam Hemmatzadeh; Faroogh Marofi; Siamak Sandoghchian Shotorbani; Mostafa Jarahian
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

10.  Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.

Authors:  Linda L Kusner; Michael J Ciesielski; Alexander Marx; Henry J Kaminski; Robert A Fenstermaker
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.